Since the pandemic, the U.S. Food and Drug Administration’s Expanded Access pathway has been featured in headlines as a mechanism by which unapproved but potentially beneficial treatments were given to patients outside randomized clinical trials.
With today’s well-known workforce challenges, it is more important than ever for sites to address workforce development in a meaningful way, reimagining the way clinical research department performs in an organizational context.
Dr. Christine Senn, Chair of the ACRP Board of Trustees, shares her outlook on the current state of the Association and the clinical research enterprise.
Improving racial and ethnic diversity of clinical trial participants is essential for generalizable, quality clinical research results and ensuring social and medical equity.
Nevada’s first integrated health system was created in June 2021 when an affiliation agreement was signed between Renown Health and the University of Nevada, Reno, School of Medicine. This expanded clinical research opportunities for patients as a core pillar of the affiliation’s mission, with the goal of providing access to novel treatments for diagnoses in addition to standard of care.